Monograph Details
|
|
Central Nervous System
> Seizure disorders
|
|
LYRICA |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
CV |
| Pharmacological Class |
|
α2-delta ligand. |
| Generic Name |
|
Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg; caps. |
| Indications |
|
Adjunct in partial onset seizures. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: Give in 2–3 divided doses. Initially 150mg/day, max 600mg/day. Renal impairment (CrCl <60mL/min): reduce dose (see literature); hemodialysis: give supplemental dose after session. |
| Precautions |
|
Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. |
| Adverse Reactions |
|
Dizziness, somnolence, other CNS effects, dry mouth, edema, ocular/visual effects (eg, blurring), weight gain, infection, asthenia, paresthesias, elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation); male-mediated teratogenicity; may be tumorigenic. |
| How Supplied |
|
Caps—90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
